These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32950499)

  • 1. Evolving targets for anti-epileptic drug discovery.
    Raut D; Bhatt LK
    Eur J Pharmacol; 2020 Nov; 887():173582. PubMed ID: 32950499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
    Weaver DF
    Epilepsia; 2013 May; 54 Suppl 2():56-9. PubMed ID: 23646972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New avenues for anti-epileptic drug discovery and development.
    Löscher W; Klitgaard H; Twyman RE; Schmidt D
    Nat Rev Drug Discov; 2013 Oct; 12(10):757-76. PubMed ID: 24052047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate drug targets for prevention or modification of epilepsy.
    Varvel NH; Jiang J; Dingledine R
    Annu Rev Pharmacol Toxicol; 2015; 55():229-47. PubMed ID: 25196047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?
    Löscher W
    Neurochem Res; 2017 Jul; 42(7):1926-1938. PubMed ID: 27502939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems biology, complexity, and the impact on antiepileptic drug discovery.
    Margineanu DG
    Epilepsy Behav; 2014 Sep; 38():131-42. PubMed ID: 24090772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible interplay between the theories of pharmacoresistant epilepsy.
    Juvale IIA; Che Has AT
    Eur J Neurosci; 2021 Mar; 53(6):1998-2026. PubMed ID: 33306252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review.
    Koshal P; Jamwal S; Kumar P
    Neuropharmacology; 2018 Jul; 136(Pt B):271-279. PubMed ID: 29129776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy.
    Vezzani A; Balosso S; Maroso M; Zardoni D; Noé F; Ravizza T
    Curr Opin Investig Drugs; 2010 Jan; 11(1):43-50. PubMed ID: 20047158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic targets for epilepsy intervention.
    Kambli L; Bhatt LK; Oza M; Prabhavalkar K
    Seizure; 2017 Oct; 51():27-34. PubMed ID: 28772199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cellular mechanisms of pharmacoresistance in epilepsy.
    Remy S; Beck H
    Brain; 2006 Jan; 129(Pt 1):18-35. PubMed ID: 16317026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs.
    Löscher W
    Seizure; 2011 Jun; 20(5):359-68. PubMed ID: 21292505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential anti-epileptic phytoconstituents: An updated review.
    Kaur J; Famta P; Famta M; Mehta M; Satija S; Sharma N; Vyas M; Khatik GL; Chellappan DK; Dua K; Khurana N
    J Ethnopharmacol; 2021 Mar; 268():113565. PubMed ID: 33166627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.
    Löscher W; Potschka H; Sisodiya SM; Vezzani A
    Pharmacol Rev; 2020 Jul; 72(3):606-638. PubMed ID: 32540959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.
    Barker-Haliski M; Steve White H
    Neuropharmacology; 2020 May; 167():107750. PubMed ID: 31469995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Marson AG; Tudur Smith C
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD001911. PubMed ID: 31318037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research advances in basic mechanisms of seizures and antiepileptic drug action.
    Lasoń W; Chlebicka M; Rejdak K
    Pharmacol Rep; 2013; 65(4):787-801. PubMed ID: 24145073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy.
    Campos G; Fortuna A; Falcão A; Alves G
    Epilepsy Res; 2018 Oct; 146():63-86. PubMed ID: 30086482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments.
    Xu C; Gong Y; Wang Y; Chen Z
    Pharmacol Ther; 2022 May; 233():108026. PubMed ID: 34718071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug.
    Doeser A; Dickhof G; Reitze M; Uebachs M; Schaub C; Pires NM; Bonifácio MJ; Soares-da-Silva P; Beck H
    Brain; 2015 Feb; 138(Pt 2):371-87. PubMed ID: 25472797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.